Core Insights - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as a promising healthcare stock with significant upside potential, supported by recent analyst ratings [1][2] - The company is focused on oncology and precision medicine, particularly through its lead asset, darovasertib, which targets uveal melanoma [3][4] Group 1: Analyst Ratings - Citizens JMP analyst Silvan Tuerkcan maintained a Buy rating for IDEAYA with a price target of $45 [1] - J.P. Morgan analyst Anupam Rama also assigned a Buy rating with a higher price target of $74 [2] Group 2: Product Development - IDEAYA's lead asset, darovasertib, is expected to have notable updates in various treatment settings, which could lead to significant value creation [3] - The company is developing IDE196, a protein kinase C inhibitor aimed at genetically defined cancers with GNAQ or GNA11 gene mutations [4]